Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 5/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 6/20 | 0.51 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20250627 | 0.89 | ELOVL1 (0.71) | ELOVL1CACNA1HCACNA1GCACNA1IABL1 | |
| SCHEMBL20250027 | 0.83 | ELOVL1 (0.72) | ELOVL1CACNA1HCACNA1GCACNA1IAR | |
| SCHEMBL20250002 | 0.81 | ELOVL1 (0.60) | ELOVL1CACNA1HCACNA1GCACNA1IGAA | |
| SCHEMBL20250000 | 0.81 | ELOVL1 (0.82) | ELOVL1CACNA1HCACNA1GCACNA1IL3MBTL1 | |
| SCHEMBL20485270 | 0.81 | ELOVL1 (0.82) | ELOVL1CACNA1HCACNA1GCACNA1IL3MBTL1 | |
| SCHEMBL20250625 | 0.80 | ELOVL1 (0.64) | ELOVL1CACNA1HCACNA1GCACNA1IGAA | |
| SCHEMBL20249957 | 0.77 | ELOVL1 (0.59) | ELOVL1CACNA1HCACNA1GCACNA1I | |
| SCHEMBL20249998 | 0.75 | ELOVL1 (0.71) | ELOVL1CACNA1HCACNA1GCACNA1IL3MBTL1 | |
| SCHEMBL20485314 | 0.74 | ELOVL1 (0.53) | ELOVL1CACNA1HCACNA1GCACNA1IGAA | |
| SCHEMBL20242035 | 0.74 | ELOVL1 (0.50) | ELOVL1CACNA1HCACNA1GCACNA1IGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | claimed |
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251431-A1 | 1,3-SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACID LEVELS | HSD17B4, CPT1A, ADH1A | ELOVL1 39/4885CACNA1H 2998/4885CACNA1G 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.